Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Editorial

The Relationship among SARS-CoV-2, Vaccine Spike Protein, Renin- Angiotensin System, and Epilepsy

Author(s): Ziad Fajloun, Layla Tajer, Hervé Kovacic and Jean-Marc Sabatier*

Volume 25, Issue 3, 2025

Published on: 22 September, 2024

Article ID: e18715265350339 Pages: 4

DOI: 10.2174/0118715265350339240919053408

TIMBC 2026
[1]
[2]
Ooi QY, Qin X, Yuan Y, et al. Alteration of excitation/inhibition imbalance in the hippocampus and amygdala of drug-resistant epilepsy patients treated with acute vagus nerve stimulation. Brain Sci 2023; 13(7): 976.
[http://dx.doi.org/10.3390/brainsci13070976] [PMID: 37508908]
[3]
Anwar H, Khan QU, Nadeem N, Pervaiz I, Ali M, Cheema FF. Epileptic seizures. Discoveries 2020; 8(2): e110.
[http://dx.doi.org/10.15190/d.2020.7] [PMID: 32577498]
[4]
Chen Z, Brodie MJ, Ding D, Kwan P. Editorial: Epidemiology of epilepsy and seizures. Front in Epidemiol 2023; 3: 1273163.
[http://dx.doi.org/10.3389/fepid.2023.1273163] [PMID: 38455942]
[5]
Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy. Neurology 2017; 88(3): 296-303.
[http://dx.doi.org/10.1212/WNL.0000000000003509] [PMID: 27986877]
[6]
Beghi E, Giussani G. Aging and the epidemiology of epilepsy. Neuroepidemiology 2018; 51(3-4): 216-23.
[http://dx.doi.org/10.1159/000493484] [PMID: 30253417]
[7]
Combined generalized and focal epilepsy. 2024. Available from: https://www.epilepsydiagnosis.org/epilepsy/focal-generalized-epilepsy-groupoverview.html
[8]
Epilepsy - Symptoms. 2017. Available from: https://www.nhs.uk/conditions/epilepsy/symptoms/
[9]
Fajloun Z, Wu Y, Cao Z, Kovacic H, Sabatier JM. COVID-19 and alzheimer’s disease: The link finally established. Infect Disord Drug Targets 2023; 23(7): 14-6.
[PMID: 37254552]
[10]
Krasniqi S, Daci A. Role of the angiotensin pathway and its target therapy in epilepsy management. Int J Mol Sci 2019; 20(3): 726.
[http://dx.doi.org/10.3390/ijms20030726] [PMID: 30744022]
[11]
Fajloun Z, Sabatier JM. The unsuspected role of the renin-angiotensin system (RAS): Could its dysregulation be at the root of all non-genetic human diseases? Infect Disord Drug Targets 2024; 24(1): e140923221085.
[http://dx.doi.org/10.2174/1871526524666230914114524] [PMID: 37711109]
[12]
Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88(9): 1-20.
[http://dx.doi.org/10.1016/S0002-9149(01)01878-1] [PMID: 11694220]
[13]
Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: Regulation, signalling and function. Blood Press 2003; 12(2): 70-88.
[http://dx.doi.org/10.1080/08037050310001057] [PMID: 12797627]
[14]
Carey RM. Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens 2005; 14(1): 67-71.
[http://dx.doi.org/10.1097/00041552-200501000-00011] [PMID: 15586018]
[15]
El-Arif G, Farhat A, Khazaal S, et al. The renin-angiotensin system: A key role in sars-cov-2-induced COVID-19. Molecules 2021; 26(22): 6945.
[http://dx.doi.org/10.3390/molecules26226945] [PMID: 34834033]
[16]
Annweiler C, Cao Z, Wu Y, et al. Counter-regulatory ‘renin-angiotensin’ system-based candidate drugs to treat COVID-19 diseases in sars-cov-2-infected patients. Infect Disord Drug Targets 2020; 20(4): 407-8.
[http://dx.doi.org/10.2174/22123989MTA2cNzIlw] [PMID: 32418532]
[17]
El-Arif G, Khazaal S, Farhat A, et al. Angiotensin II type i receptor (AT1R): The gate towards COVID-19-associated diseases. Molecules 2022; 27(7): 2048.
[http://dx.doi.org/10.3390/molecules27072048] [PMID: 35408447]
[18]
Khazaal S, Harb J, Rima M, et al. The pathophysiology of long COVID throughout the renin-angiotensin system. Molecules 2022; 27(9): 2903.
[http://dx.doi.org/10.3390/molecules27092903] [PMID: 35566253]
[19]
Sabatier J-M, Fajloun Z, Legros C. COVID-19 and ehlers-danlos syndrome: The dangers of the spike protein of sars-cov-2. Infect Disord Drug Targets 2023; 23(3): e040123212375.
[http://dx.doi.org/10.2174/1871526523666230104145108] [PMID: 36600622]
[20]
Fajloun Z, Abi Khattar Z, Kovacic H, Legros C, Sabatier JM. Why do athletes develop very severe or fatal forms of COVID after intense exercise following sars-cov-2 infection or anti-COVID vaccination? Infect Disord Drug Targets 2023; 23(4): e110123212563.
[http://dx.doi.org/10.2174/1871526523666230111104355] [PMID: 36631923]
[21]
Fajloun Z, Abi Khattar Z, Kovacic H, Legros C, Sabatier JM. SIBO: The trail of a “new” human pathology associated with multiple severe and disabling COVID-19 and long COVID symptoms or induced by the anti-COVID-19 vaccine. Infect Disord Drug Targets 2023; 23(4): e100223213593.
[http://dx.doi.org/10.2174/1871526523666230210162334] [PMID: 36762752]
[22]
Fajloun Z, Abi Khattar Z, Kovacic H, Legros C, Sabatier JM. Anti-COVID-19 vaccination, COVID-19, and female contraception: The exacerbated risks (thromboembolism) of the estrogen-progestin pill. Infect Disord Drug Targets 2023; 23(4): e240223214000.
[http://dx.doi.org/10.2174/1871526523666230224094439] [PMID: 36823996]
[23]
Fajloun Z, Abi Khattar Z, Kovacic H, Legros C, Sabatier JM. Understanding and relieving of neuropathic disorders in the long COVID. Infect Disord Drug Targets 2023; 23(4): e270223214061.
[http://dx.doi.org/10.2174/1871526523666230227113205] [PMID: 36843369]
[24]
Fajloun Z, Abi Khattar Z, Kovacic H, Sabatier JM. COVID-19 and anti-COVID-19 vaccination: potential damages to the thyroid gland. Infect Disord Drug Targets 2023; 23(6): e090523216698.
[http://dx.doi.org/10.2174/1871526523666230509112038] [PMID: 37165584]
[25]
Fajloun Z, Wu Y, Cao Z, Kovacic H, Sabatier JM. COVID-19 and parkinson’s disease: the link also established! Infect Disord Drug Targets 2023.
[PMID: 37340743]
[26]
Fajloun Z, Khattar ZA, Sabatier JM. The intriguing connection between cholestasis and the renin-angiotensin system dysregulation induced by sars-cov-2 and/or the vaccinal spike protein. Infect Disord Drug Targets 2024; 24(7): e080324227802.
[http://dx.doi.org/10.2174/0118715265304515240220105152] [PMID: 38465438]
[27]
Tajer L, Paillart JC, Dib H, Sabatier JM, Fajloun Z, Abi Khattar Z. Molecular mechanisms of bacterial resistance to antimicrobial peptides in the modern era: An updated review. Microorganisms 2024; 12(7): 1259.
[http://dx.doi.org/10.3390/microorganisms12071259] [PMID: 39065030]
[28]
Fajloun Z, Abi Khattar Z, Sabatier JM. SARS-CoV-2 or vaccinal spike protein can induce mast cell activation syndrome (MCAS). Infect Disord Drug Targets 2024; 24: 1-3.
[PMID: 38693735]
[29]
Fajloun Z, Tajer L, Khattar ZA, Sabatier JM. Unveiling the role of SARS-CoV-2 or mRNA vaccine spike protein in macrophage activation syndrome (MAS). Infect Disord Drug Targets 2024; 24.
[PMID: 39041264]
[30]
Quarleri J, Delpino MV. SARS-CoV-2 interacts with renin-angiotensin system: Impact on the central nervous system in elderly patients. Geroscience 2022; 44(2): 547-65.
[http://dx.doi.org/10.1007/s11357-022-00528-0] [PMID: 35157210]
[31]
Soltani Zangbar H, Gorji A, Ghadiri T. A review on the neurological manifestations of COVID-19 infection: A mechanistic view. Mol Neurobiol 2021; 58(2): 536-49.
[http://dx.doi.org/10.1007/s12035-020-02149-0] [PMID: 32981023]
[32]
Ivanova N, Tchekalarova J. The potential therapeutic capacity of inhibiting the brain renin–angiotensin system in the treatment of co-morbid conditions in epilepsy. CNS Drugs 2019; 33(11): 1101-12.
[http://dx.doi.org/10.1007/s40263-019-00678-4] [PMID: 31680223]
[33]
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls. Treasure Island, FL: StatPearls Publishing 2024.
[34]
Al-Jamal H, Idriss S, Roufayel R, Abi Khattar Z, Fajloun Z, Sabatier JM. Treating COVID-19 with medicinal plants: Is it even conceivable? A comprehensive review. Viruses 2024; 16(3): 320.
[http://dx.doi.org/10.3390/v16030320] [PMID: 38543686]
[35]
Dong X, Fan J, Lin D, et al. Captopril alleviates epilepsy and cognitive impairment by attenuation of C3-mediated inflammation and synaptic phagocytosis. J Neuroinflammation 2022; 19(1): 226.
[http://dx.doi.org/10.1186/s12974-022-02587-8] [PMID: 36104755]
[36]
Gomes KP, Braga PPP, de Lima CQ Jr, et al. Antiepileptic effects of long-term intracerebroventricular infusion of angiotensin-(1-7) in an animal model of temporal lobe epilepsy. Clin Sci 2020; 134(17): 2263-77.
[http://dx.doi.org/10.1042/CS20200514] [PMID: 32803259]
[37]
Doege C, Luedde M, Kostev K. Association between angiotensin receptor blocker therapy and incidence of epilepsy in patients with hypertension. JAMA Neurol 2022; 79(12): 1296-302.
[http://dx.doi.org/10.1001/jamaneurol.2022.3413] [PMID: 36251288]

© 2025 Bentham Science Publishers | Privacy Policy